These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Akhtar M; Islam MR; Khaton F; Soltana UH; Jafrin SA; Rahman SIA; Tauheed I; Ahmed T; Khan II; Akter A; Khan ZH; Islam MT; Khanam F; Biswas PK; Ahmmed F; Ahmed S; Rashid MM; Hossain MZ; Alam AN; Alamgir ASM; Rahman M; Ryan ET; Harris JB; LaRocque RC; Flora MS; Chowdhury F; Khan AI; Banu S; Shirin T; Bhuiyan TR; Qadri F Front Immunol; 2023; 14():1309997. PubMed ID: 38173725 [TBL] [Abstract][Full Text] [Related]
5. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
6. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096 [TBL] [Abstract][Full Text] [Related]
9. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
10. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G Front Immunol; 2021; 12():737083. PubMed ID: 34539673 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the Serial Humoral Immune Response according to the Immunosuppressive Treatment after SARS-CoV-2 mRNA Vaccination. Menjo H; Hasegawa M; Fujigaki H; Ishihara T; Minatoguchi S; Koide S; Hayashi H; Saito M; Takahashi K; Ito H; Yuzawa Y; Saito K; Tsuboi N Intern Med; 2023 Dec; 62(23):3445-3454. PubMed ID: 37779074 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596 [TBL] [Abstract][Full Text] [Related]
13. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines. Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Nabeshima S; Hiromatsu K Int J Infect Dis; 2024 Feb; 139():1-5. PubMed ID: 38029832 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
15. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D Front Immunol; 2022; 13():1017863. PubMed ID: 36248803 [TBL] [Abstract][Full Text] [Related]
16. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC Front Immunol; 2022; 13():920333. PubMed ID: 35865529 [TBL] [Abstract][Full Text] [Related]
17. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases. Anderson E; Powell M; Yang E; Kar A; Leung TM; Sison C; Steinberg R; Mims R; Choudhury A; Espinosa C; Zelmanovich J; Okoye NC; Choi EJ; Marder G; Narain S; Gregersen PK; Mackay M; Diamond B; Levy T; Zanos TP; Khosroshahi A; Sanz I; Luning Prak ET; Bar-Or A; Merrill J; Arriens C; Pardo G; Guthridge J; James J; Payne A; Utz PJ; Boss JM; Aranow C; Davidson A JCI Insight; 2024 Jun; 9(13):. PubMed ID: 38833310 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939 [TBL] [Abstract][Full Text] [Related]
20. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L Front Immunol; 2022; 13():829665. PubMed ID: 35154152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]